Kelun-Biotech: A New Contender in Lung Cancer Treatment
You don't find this kind of excitement every day in the biotech sector. Kelun-Biotech is shaking up the oncology world with its presentation of two pivotal studies at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. They're tossing their hat into the ring with some serious innovation for non-small cell lung cancer (NSCLC). If there's one thing I've learned over the decades, it's that data doesn't lie, and Kelun's results are nothing to shrug at.
Sacituzumab Tirumotecan: Promising First-Line NSCLC Treatment
Let's dig into the details. Kelun's study on sacituzumab tirumotecan (sac-TMT) combined with pembrolizumab versus pembrolizumab alone for PD-L1 positive advanced NSCLC throws down a gauntlet. The significant edge they show in progression-free survival (PFS) is noteworthy—a median PFS not reached yet versus a plain 5.7 months for pembrolizumab alone. We're talking a hazard ratio of 0.35, a game-changer in keeping cancer at bay. The whispers about the overall survival trend are optimistic too. Not fully mature, but enough to keep investors attentive. The drug's approval journey seems smoother already with an sNDA under priority review in China—a move that positions Kelun-Biotech as one to watch if you're holding ticker 6990.HK.
"This unique combination sets a new benchmark for first-line NSCLC treatment," said a Kelun-Biotech spokesperson during the study release.
But keep your boots on—adverse events weren't minor. A tick over half experienced Grade 3 treatment-emergent side effects in the combo arm. Still, it's all about balancing efficacy and safety in this grueling sector, and Kelun's swinging at the moats of giants like Merck with their sac-TMT combo, seeking a robust frontline position against NSCLC.
Lunbotinib Fumarate: A Beacon for RET-Fusion Positive NSCLC?
On the other front, lunbotinib fumarate is pushing boundaries for patients with RET-fusion positive NSCLC. With a confirmed objective response rate (ORR) of over 80% across pre-treated and treatment-naïve patients, it's the sort of reassurance that investors crave. A PFS of 27.5 months in pre-treated folks? That's no small feat. Their study has no inflated rhetoric—just solid statistics indicating Kelun-Biotech might genuinely have a competitor on its hands, pending regulatory nods.
- High ORR: 87.1% in pre-treated, 81.3% in treatment-naïve.
- Promising PFS: 27.5 months for pre-treated patients.
- OS rates: Strong indications, suggesting longevity in treatment efficacy.
The safety aspect here, though, was relatively manageable. Only 40.5% reported serious treatment-related adverse events. Practically speaking, keeping this under control is crucial to move smoothly past the NMPA's scrutinizing eyes.
Strategic Moves: Collaboration and Global Ambitions
Make no mistake: Kelun isn't operating in a vacuum. Partnerships denote their strategic acumen. They've licensed sac-TMT rights to MSD, aiming to broaden their global footprint beyond China's borders. Similarly, they've set lunbotinib fumarate's international development and commercialization in the hands of Ellipses Pharma Limited. It's a savvy strategy—pushing into new markets while holding strong on home turf.
Given where Kelun stands, it's an intriguing time for investors tracking the biotech landscapes. Their ambitious pipeline, with over 30 ongoing innovative projects, evidences their quest not just to talk the talk but to walk it too. Pivotal developments like these reshape the contours of care and investment landscapes alike, making Kelun-Biotech a stirring narrative at ASCO 2026.
